Ursoliv, 250 mg capsules 100 pcs

Ursoliv – Hepatoprotector.

The active component is ursodeoxycholic acid.

The medicine has cholitholytic, choleretic, hypocholesterolemic, hypolipidemic and immunostimulatory effects.

Researches have shown that the active substance reduces hepatotoxicity of bile acids salts and has a pronounced protective effect on liver cells.

The drug Ursoliv reduces cholesterol levels by reducing its adsorption in the intestinal lumen.

The drug is able to destroy cholesterol-containing stones in the gallbladder.

The active substance stimulates the formation and excretion of bile, as well as the excretion of toxic acids through the intestinal lumen.

Ursodeoxycholic acid increases the secretion of gastric and pancreatic juices, increases lipase activity and has hypolipidemic effect.

An immunomodulatory effect is achieved by reducing the number of eosinophils, suppressing interleukin production and reducing antigen expression.

Indications

Gallstone disease
Biliary reflux gastritis.
Primary biliary cirrhosis in the absence of signs of decompensation (symptomatic therapy);
Dissolution of small and medium-sized cholesterol stones with a functioning gallbladder;

Pharmacological effect

Ursoliv – Hepatoprotector.

The active ingredient is ursodeoxycholic acid.

The medication has cholelitholytic, choleretic, hypocholesterolemic, hypolipidemic and immunostimulating effects.

Scientific studies have shown that the active substance reduces the hepatotoxicity of bile salts and has a pronounced protective effect on liver cells.

The drug Ursoliv reduces cholesterol levels by reducing its adsorption in the intestinal lumen.

The drug is able to destroy cholesterol-containing gallstones.

The active substance stimulates the formation and discharge of bile, as well as the excretion of toxic acids through the intestinal lumen.

Ursodeoxycholic acid enhances the secretion of gastric and pancreatic juice, increases lipase activity, and has a hypolipidemic effect.

By reducing the number of eosinophils, suppressing the production of interleukins, and reducing the expression of antigens, an immunomodulatory effect is achieved.

Special instructions

To dissolve gallstones with UDCA, the stones must be cholesterol (not radiopaque) and no larger than 15-20 mm in size. In this case, the gallbladder must remain functional, and the patency of the cystic and common bile ducts must be preserved.

When prescribed for the purpose of dissolving gallstones, it is necessary monthly, and then every 3 months. carry out a biochemical blood test to determine the activity of “liver” transaminases, alkaline phosphatase, gamma-glutamyl transpeptidase, as well as bilirubin concentration.

If elevated levels persist, the drug should be discontinued.
To monitor the effectiveness of treatment, it is recommended every 6 months. conduct x-ray and ultrasound examination of the biliary tract.

If there is calcification of gallstones, impaired contractility of the gallbladder, or frequent attacks of biliary colic, treatment should be discontinued.

If partial dissolution of the stones does not occur within 6-12 months after the start of therapy, it is unlikely that the treatment will be effective.

The discovery of a non-visualized gallbladder during treatment is evidence that complete dissolution of the stones has not occurred and treatment should be discontinued.

After complete dissolution of stones, to avoid relapses, it is recommended to continue using ursodeoxycholic acid for 3 months.

The drug does not have a negative effect on the ability to drive vehicles and/or other mechanisms.

Active ingredient

Ursodeoxycholic acid

Composition

Active ingredient:

ursodeoxycholic acid 250 mg.

Excipients:

lactulose,

microcrystalline cellulose,

low molecular weight povidone,

magnesium stearate,

talc.

Pregnancy

Contraindicated.

Contraindications

acute cholecystitis
cirrhosis
severe renal and/or liver dysfunction.

Side Effects

Allergic reactions.

Interaction

When used together, antacids containing aluminum and ion exchange resins (cholestyramine) reduce the absorption of UDCA.

When used concomitantly, lipid-lowering drugs (especially clofibrate), estrogens, neomycin or progestogens (oral contraceptives) increase the saturation of bile with cholesterol and may reduce the ability of ursodeoxycholic acid to dissolve cholesterol gallstones.

When used concomitantly, UDCA may increase the absorption of cyclosporine.

Storage conditions

Store in a dry place, protected from light, at a temperature not exceeding 25°C.

Shelf life

4 years.

Manufacturer

ABVA RUS, Russia